LOXL2 and metabolic dysfunction-associated steatohepatitis: As the first LOX family member to be specifically targeted, the anti-LOXL2 mAb simtuzumab was broadly evaluated in phase 2 clinical studies for patients with myelofibrosis,24 idiopathic pulmonary fibrosis (IPF),25 HCV/HIV-induced advanced liver fibrosis,26 NASH-associated bridging fibrosis/compensated cirrhosis,17 and primary sclerosing cholangitis (PSC).27